A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
For more than 90 years, Bergonié Institute has contributed to medical progress and to the international influence of research in the prevention, detection and treatment of cancer, a chronic disease which has become the second leading cause of death in the world.
Bordeaux, France Clinical Trial Location
229 Cours de l’Argonne,
33000 Bordeaux, France